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Background: Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and
mitochondrial trifunctional protein (MTP) deficiencies are rare autosomal recessive
fatty acid β-oxidation disorders. Their clinical presentations are variable, and premature
death is common. They are included in newborn blood spot screening programs in many
countries around the world. The current process of screening, through the measurement
of acylcarnitines (a metabolic by-product) in dried blood spots with tandem mass
spectrometry, is subject to uncertainty regarding test accuracy.
Methods: We conducted a systematic review of literature published up to 19th June
2018. We included studies that investigated newborn screening for LCHAD or MTP
deficiencies by tandem mass spectrometry of acylcarnitines in dried blood spots. The
reference standards were urine organic acids, blood acylcarnitine profiles, enzyme
analysis in cultured fibroblasts or lymphocytes, mutation analysis, or at least 10-year
follow-up. The outcomes of interest were sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV). Assessment of titles, abstracts, and full-text
papers and quality appraisal were carried out independently by two reviewers. One
reviewer extracted study data. This was checked by a second reviewer.
Results: Ten studies provided data on test accuracy. LCHAD or MTP deficiencies
were identified in 23 babies. No cases of LCHAD/MTP deficiencies were identified
in four studies. PPV ranged from 0% (zero true positives and 28 false positives
from 276,565 babies screened) to 100% (13 true positives and zero false positives
from 2,037,824 babies screened). Sensitivity, specificity, and NPV could not be
calculated as there was no systematic follow-up of babies who screened negative.
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Conclusions: Test accuracy estimates of screening for LCHAD and MTP deficiencies
with tandem mass spectrometry measurement of acylcarnitines in dried blood were
variable in terms of PPVs. Screening methods (including markers and thresholds) varied
between studies, and sensitivity, specificity, and NPVs are unknown.
Keywords: systematic review, test accuracy, LCHAD deficiency, MTP deficiency, newborn blood spot screening
INTRODUCTION
Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and
mitochondrial trifunctional protein (MTP) deficiencies (Enzyme
Commission Number 1.1.1.211) are recessive autosomal fatty
acid β-oxidation disorders. They are caused by mutations in
the genes coding for MTP. LCHAD deficiency arises as a
result of mutations in the HADHA gene; MTP deficiency
arises from mutations in HADHA and HADHB genes (1).
The conditions are characterized by lethargy, hypoglycemia,
hypotonia, cardiomyopathy, and acute metabolic crisis (2,
3). Long-term complications include liver disease, peripheral
neuropathy, and retinopathy (3, 4). Signs and symptoms may
present immediately after birth or later in life (5). Three main
forms of LCHAD/MTP deficiencies have been reported: an
early-onset form, which is associated with cardiomyopathy,
hypoglycemia, and sudden infant death; an infant-onset form,
which is characterized by recurrent hypoketotic hypoglycemia
and lethargy during illness or fasting; and a milder, late-onset
form that is triggered by exercise, fasting, or infections and is
associated with progressive peripheral neuropathy and recurrent
rhabdomyolysis (6, 7). There is no cure for LCHAD or MTP
deficiencies, and premature death is common. Approximately
38% of infants die before, or within 3 months of, diagnosis (5). A
number of management strategies are available, namely a high-
carbohydrate and fat-modified/decreased diet that is low in long-
chain fatty acids, supplements (L-carnitine, docosahexaenoic
acid, and medium-chain triglyceride oil, such as triheptanoin),
and avoidance of fasting (1). There is some evidence that
these treatments are associated with improved clinical outcomes
(e.g., reduced mortality, delayed visual complications), but the
effects are variable, study sample sizes are small, and few data
are available from long-term follow-up studies (1, 8–10). The
incidence of LCHAD and MTP deficiencies varies widely around
the world. A recent estimate from the USA gives an incidence
of 1:363,738 for LCHAD deficiency and 1:1,240,467 for MTP
deficiency (11).
It has been proposed that earlier recognition and treatment
of LCHAD/MTP deficiencies may be critical for improving
health outcomes (5), and the two conditions are included in
Abbreviations: C14OH, 3-hydroxytetradecanoylcarnitine; C14:1,
tetradecenoylcarnitine; C16OH, 3-hydroxypalmitoylcarnitine; C16OH/C16,
3-hydroxypalmitoylcarnitine/palmitoylcarnitine; C16:1OH, 3-hydroxypalmi
toleylcarnitine; C18OH, 3-hydroxystearoylcarnitine; C18:1OH, 3-
hydroxyoleoylcarnitine; C18:1, oleoylcarnitine; DBS, dried blood spot; FP,
false positive; LCHAD, long-chain 3-hydroxyacyl-CoA dehydrogenase; MTP,
mitochondrial trifunctional protein; NPV, negative predictive value; PPV, positive
predictive value; QUADAS-2, Quality Assessment Tool for Diagnostic Accuracy
Studies 2; TMS, tandem mass spectrometry; TP, true positive.
newborn screening programs in many countries. Screening is
conducted through the measurement of acylcarnitines (primarily
C16OH, C16:1 OH, C18OH) in dried blood spots using
tandem mass spectrometry (TMS). These markers are not
specific to LCHAD/MTP deficiencies, however, and levels can be
raised in other conditions (e.g., carnitine palmitoyltransferase II
deficiency, very long-chain acyl-CoA dehydrogenase deficiency)
and in babies of very low birth weight/being treated in
neonatal intensive care (12). The results of a recent report from
the UK suggest that screening for LCHAD/MTP deficiencies
would not lead to the identification of additional cases as
compared with the current practice of clinical detection (13).
In contrast, data from other countries have suggested that
screening does lead to earlier detection of LCHAD/MTP
deficiencies (14, 15).
To date, there has been one systematic review examining
test accuracy of screening for LCHAD/MTP deficiencies (16).
Searching up to 2012, Einoder-Moreno et al. (16) identified
six studies and concluded that sensitivity, specificity, and
negative predictive value (NPV) of acylcarnitine measurement
in dried blood spots are close to 100%, and that the positive
predictive value (PPV) ranges from 9 to 100%. However,
three relevant papers were missed by their search (12, 17, 18),
and the calculation of sensitivity, specificity, and negative
predictive value were based on an assumption about the
disease status of babies who screened negative, as no follow-
up of these babies was conducted in the included studies.
This approach can lead to overestimation of sensitivity
and underestimation of specificity (19). The aim of the
current paper, therefore, is to conduct a systematic review
of test accuracy metrics (sensitivity, specificity, positive and
negative predictive values) of acylcarnitine measurement in
newborn screening dried blood spots (DBS) for LCHAD/MTP
deficiencies using tandem mass spectrometry using a
broader search than the previous review and taking into
consideration whether or not babies who screen negative
received follow-up assessment.
MATERIALS AND METHODS
The review protocol is registered at PROSPERO (registration
number CRD42018094356).
Search Strategy
We conducted a search of the following electronic databases:
MEDLINE, MEDLINE In-Process, MEDLINE Daily, MEDLINE
ePub Ahead of Print, the Cochrane Library, Web of Science,
and Embase. Search terms (free text and subject headings)
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related to the disease area (e.g., “mitochondrial trifunctional
protein,” “long-chain-3-hydroxyacyl-CoA dehydrogenase,”
“fatty acid oxidation disorder”) and screening (e.g., “newborn
screening,” “dried blood spot,” “tandem mass spectrometry”).
Full details of the search are provided in Supplement 1. The
reference lists of included articles and relevant systematic reviews
were also examined. The search was conducted on 19th June
2018, with no restrictions on the publication date or language
of articles.
Eligibility Criteria
We included journal articles and reports that investigated
newborn screening for LCHAD or MTP deficiencies by TMS
analysis of acylcarnitines in dried blood spots. The reference
standards were urine organic acids, blood acylcarnitine profiles,
enzyme analysis in cultured fibroblasts or lymphocytes, mutation
analysis, or at least 10-year follow-up. These could be on
their own or in any combination. Appropriate study designs
were cross-sectional test accuracy studies, case-control studies,
and cohort studies. The outcomes of interest were sensitivity,
specificity, PPV, and NPV (or sufficient data to allow us
to calculate these). We excluded non-human studies, letters,
editorials, communications, conference abstracts, gray literature,
studies of fatty acid β-oxidation disorders where data for
LCHAD/MTP deficiencies could not be separated from data for
other conditions, studies with no extractable data, and studies
where more than 10% of the study sample did not meet our
inclusion criteria.
Screening and Data Extraction
Titles, abstracts, and full-text papers were independently
screened by two reviewers. Data extraction was conducted by a
single reviewer and checked by a second reviewer. At each stage
of the review, disagreements were resolved through discussion
between the reviewers, with the involvement of a third reviewer
if consensus could not be achieved.
Quality Appraisal
Two reviewers independently assessed risk of study bias and
applicability concerns using the Quality Assessment Tool
for Diagnostic Accuracy Studies (QUADAS-2) (20), which
was tailored to the research question. Tailoring comprised
defining cut-offs for exclusions, identifying appropriate reference
standards, selecting a suitable interval between index tests
and reference standards, and producing guidance notes.
Disagreements were resolved through discussion by the two
reviewers, leading to a consensus on assessment of risk of
bias and applicability concerns for all studies. The QUADAS-
2 tool is presented in Supplement 2 and the guidance notes in
Supplement 3.
Data Summary and Synthesis
Due to incomplete 2 × 2 tables and heterogeneity between study
designs, a narrative summary of the evidence is provided. We
calculated confidence intervals for test accuracy metrics using the
Wilson score method with continuity correction (21).
RESULTS
Searching, Sifting, and Sorting
Full details of the flow of studies through the review are outlined
in Figure 1. One thousand one hundred and ninety-four unique
records were identified through searching electronic databases.
After examination of titles and abstracts, 39 papers were retained
for full-text assessment. Eleven of these papers met the review’s
inclusion criteria (12–15, 17, 18, 22–26). Two papers included
overlapping cohorts (17, 22). Only the data from the larger, more
recent paper by Lindner et al. (17) [which included all of the data
from Schulze et al. (22)] are reported here. A list of excluded
studies [with reasons for exclusion] is provided in Supplement 4.
Quality Appraisal
A summary of the risks of bias and applicability concerns of the
included papers is provided in Figure 2. Ratings of risks of biases
and applicability concerns for each individual study are provided
in Supplement 5.
Risk of bias was considered to be high in two or more domains
for nine of the 10 studies (90%) (12–14, 17, 18, 23–26) and in
one domain for the remaining study (10%) (15). In the patient
selection domain, risk of bias was rated as unclear in seven (70%)
studies due to unclear/incomplete reporting (12, 15, 17, 23–
26), and low in three (30%) studies (13, 14, 18). There were
considerable concerns regarding applicability to the UK context
in seven (70%) studies as blood samples were taken before day 5
in six studies (12, 15, 17, 18, 23, 25), and the incidence of MTPD
was lower than expected in one study (1:300,000 compared with
1:149,254 in the UK) (24). Applicability concerns were unclear in
two studies (14, 26) and low in one study (13).
In the index test domain, five studies (50%) were rated as
having high risk of bias as the cut-off for “screen positive” was
altered during the study period (13) or was not pre-specified
(12, 23, 24, 26). Of the remaining studies, two were at unclear
risk of bias (18, 25) and three were at low risk of bias (14,
15, 17). Two (20%) studies had high applicability concerns as
one included additional markers (C14:1, C14-OH) (15) and
one included both blood and urine samples (18). Applicability
concerns were unclear in two studies (17, 25) and low in six
studies (12–14, 23, 24, 26).
In the reference standard domain, risk of bias was rated
as unclear in all 10 studies because it was not possible to
tell the reference standard results were interpreted without
knowledge of the results of the index test (12–15, 17, 18,
23–26). Applicability concerns were unclear in six (60%)
studies (12, 15, 23–26) and low in the remaining four
(40%) (13, 14, 17, 18).
Finally, all studies were judged to be at high risk of bias in
the flow and timing domain (12–15, 17, 18, 23–26). The reasons
for this were that the reference standards used to confirm disease
status for screen positives and screen negatives were not the
same, follow-up of those children who screened negative was
not defined or not conducted, and losses to follow-up were
not reported.
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FIGURE 1 | PRISMA flow diagram of records through the systematic review. *See Supplement 4 for list of excluded studies with reasons.
FIGURE 2 | Risk of bias and applicability concern graph: review authors’ judgments about each domain presented as percentages across included studies.
Characteristics of Included Studies
Details of the included studies are provided in Table 1 and
Supplement 6. Ten studies were included, four pilot programs
(12, 13, 23, 25), three mixed pilot and national/regional screening
programs (14, 17, 24), and three national/regional screening
programs (15, 18, 26). Six studies took place in Europe [Denmark,
Faroe Islands, and Greenland (14), Germany (15, 17), Slovenia
(23), Spain (18), UK (13)], two in Asia (China (26), Hong
Kong (25)), and two in North America [USA (12, 24)]. Sample
sizes ranged from 2,440 (25) to 1,200,000 (15). In total, the
10 studies screened 3,951,358 newborns. Twenty-three true
positives (TP) and 40 false positives (FP) were identified. The 23
true positives comprised 11 babies with LCHAD deficiency, two
with MTP deficiency, and 10 babies for whom LCHAD and MTP
deficiencies were not differentiated.
Description of Screening and Diagnostic
Tests
Details of the screening methodology and diagnostic
tests used in each study are provided in Supplement 6.
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2 × 2 table Test accuracya









Couce et al. (18) 210,165 C16OH,
C18:1OH,
C18OH
NR 2b 0 NR NR NA NA 1
(0.20, 1)
NA



























0 NR NR NA NA 1
(0.52, 1)
NA






3c 0 NR NR NA NA 1
(0.31, 1)
NA
Mak et al. (25) 2,440 Unclear Unclear 0 2 NR NR NA NA 0
(0, 0.80)
NA


























0 8 NR NR NA NA 0
(0, 0.40)
NA

































0.1e 0 5 NR NR NA NA 0
(0, 0.54)
NA
aConfidence intervals calculated using Wilson score method with continuity correction. bLCHAD deficiency. cLCHAD/MTP deficiencies. dData provided by study authors. eDetermined
during the study to ensure that no more than 0.02% of population would be flagged. CI, confidence interval; FN, false negative; FP, false positive; LCHADD, long-chain 3-hydroxyacyl-CoA
dehydrogenase deficiency; MTPD, mitochondrial trifunctional protein deficiency; NA, not applicable; NBS, newborn bloodspot; NPV, negative predictive value; NR, not reported; PPV,
positive predictive value; TN, true negative; TP, true positive; UK NSC, UK National Screening Committee. *The values were calculated by the review authors.
In brief, eight different analytes or ratios were
used as markers to screen for LCHAD/MTP
deficiencies: 3-hydroxytetradecanoylcarnitine (C14OH),
tetradecenoylcarnitine (C14:1), 3-hydroxypalmitoylcarnitine
(C16OH), 3-hydroxypalmitoleylcarnitine (C16:1OH), 3-
hydroxystearoylcarnitine (C18OH), 3-hydroxyoleoylcarnitine
(C18:1OH), oleoylcarnitine (C18:1), and 3-
hydroxypalmitoylcarnitine/palmitoylcarnitine (C16OH/C16),
with each study employing a unique combination. The cut-offs
used varied between studies (e.g., cut-offs ranged from >0.04
to >0.20 µmol/L for C16OH, >0.03 to >0.15 µmol/L for
C18OH, and >0.05 to >0.14 µmol/L for C18:1OH), with no two
studies using the same combination of markers and thresholds.
Screening samples were collected between 24 h and day 37 of life
(25, 26).
The reference standards used varied between and within
studies. For screen-positive babies, reference standards were
blood acylcarnitines, urinary organic acids, and DNA analysis
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(13, 24, 25); enzyme and/or molecular studies (18); enzyme
activity in fibroblasts/lymphocytes and mutation analysis (15);
acylcarnitine profile in plasma/DBS and/or genotype and/or
enzyme activity (17); urine organic acids, plasma acylcarnitines,
and molecular-genetic analyses (14); organic acid in urine, next-
generation sequencing, and an additional acylcarnitine profile in
DBS (23); and urinary organic acids or DNA analysis (26). Lastly,
one study used “standard metabolic criteria” (12). No systematic
follow-up of babies who screened negative was conducted in any
of the studies.
Accuracy of Screening Tests
The cut-offs used to classify a positive case of LCHAD/MTP
deficiencies and the diagnostic tests used to confirm this varied
between studies. Therefore, we report positive screening results
as those that met/exceeded the cut-off and were diagnostically
confirmed as presented in the individual study. Test accuracy
data are show in Table 1.
Positive and Negative Predictive Values
PPV varied considerably between studies. It was 0% in four
studies, with zero true positives and 28 false positives from
276,565 babies screened (12, 23, 25, 26), 33% in one study, with
one true positive and two false positives from 436,969 babies
screened (13), 47% in one study, with 9 true positives and 10
false positives from 1,200,000 babies screened (15), and 100%
in four studies, with 13 true positives from 2,037,824 babies
screened (14, 17, 18, 24). In the UK study, the single case reported
as a true positive was being treated for LCHADD at the point
of screening, as they had already been detected clinically (13).
Confidence intervals were wide due to the small number of cases
of LCHAD/MTP deficiencies detected (23 in total, zero to nine
per study). It was not possible to calculate NPV as newborns who
screened negative were not systematically followed up.
Sensitivity and Specificity
We were not able to determine sensitivity or specificity due to a
lack of information on babies who screened negative.
DISCUSSION
We assessed the test accuracy of acylcarnitine measurement
in newborn DBS using TMS for LCHAD/MTP deficiencies.
Ten relevant studies were identified. All studies had a high
risk of bias in at least one domain, and 9/10 (90%) studies
had a high risk of bias in at least two domains. Across the
10 studies, ∼4,000,000 babies were screened and 23 cases of
LCHAD/MTP deficiencies were identified; 11 babies had LCHAD
deficiency, two had MTP deficiency, and 10 had undifferentiated
LCHAD/MTP deficiencies. One of the cases reported as a true
positive had already been detected clinically at the point at which
screening took place (13). Arguably, the PPV for this study
should be 0% rather than 33%, as reported in the study. Forty
additional babies screened positive but were subsequently found
not to have LCHAD or MTP deficiency. In four studies, no cases
of LCHAD/MTP deficiencies were identified (12, 23, 25, 26).
However, in three of these studies, the sample sizes were too small
to be likely to detect such rare diseases [screening population
sizes were 2,440 (25), 10,048 (23), and 100,077 (26)]. The fourth
study included a larger sample (n = 164,000) but only included
one marker (C16OH), which might have made the screening
process less accurate (12).
The only measure of test accuracy that was consistently
reported (or where sufficient data were present to allow us to
calculate it) was PPV. PPV in the 10 studies ranged from 0%
(zero true positives and 28 false positives from 276,565 babies
screened) to 100% (13 true positives from 2,037,824 babies
screened). It was not possible to calculate sensitivity, specificity,
or NPV as there was no systematic follow-up of babies who
had screened negative. In a pilot or national screening program
for a rare disease using a “promising” test, negative tests will
inevitably represent the vast majority of test results. While
some studies provided very high PPV, PPV is not intrinsic to
the test itself, and at any particular values of sensitivity and
specificity, the estimates of PPV (and also NPV) are strongly
dependent on disease prevalence. This relationship is illustrated
in Supplement 7 over a range of prevalence values similar to
those in the included studies and over a range of specificity
values. In order to provide a complete assessment of test
accuracy, all four metrics (sensitivity, specificity, NPV, PPV)
are required.
Whether newborn screening for LCHAD/MTP deficiencies
with acylcarnitines measurement in dried blood spots using TMS
is appropriate is currently unclear due to a lack of data on
babies who screen negative and a lack of consistency between
screening test methods. Partial verification bias is a key issue
in the included studies; from nearly 4,000,000 babies screened,
only 63 (those who screened positive) received a reference
standard. Therefore, we cannot know the true disease state of
the babies who screened negative. Partial verification bias is
common in studies of test accuracy because it is often impractical,
unethical, and not cost-effective to follow-up every participant.
Alternative approaches to whole population follow-up include
statistical methods to attempt to correct for the bias, follow-up
of samples of participants who screen negative, and searching
disease registers to find false negatives. Statistical methods may
introduce other forms of bias (27, 28).
There were substantial differences between screening test
methods. For example, there were differences in the extraction
and calibration methods (in-house or commercially available
test kits); analysis as acylcarnitine butyl esters or free acids
(underivatised); screening markers used (e.g., C14OH, C14:1,
C16OH, C16:1OH, C18OH, C18:1, C18:1OH, C16OH/C16
ratio); whether markers were employed in isolation or in
combination with each other [two studies did not report which
marker(s) were used (18, 25)] and variability in the cut-offs
between studies, with cut-offs not specified in three studies (18,
23, 25). The majority of FP were found in studies which used
lower thresholds for C16OH (>0.03 to>0.10µmol/L), C16:1OH
(>0.04 to 0.15 µmol/L), and C18:1OH (>0.01 to 0.06 µmol/L).
While screening for LCHADD/MTP is conducted in the
newborn bloodspot programs of a number of countries, there
is little published data on the benefits and harms of these.
Taylor-Phillips et al. (29) reviewed the evidence on national
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policy recommendations on screening newborn babies for rare
diseases. They highlight three elements that might determine
the balance of benefits and harms from screening programs:
test accuracy, the benefit of early detection and treatment,
and overdiagnosis (the detection and subsequent treatment
of disease that would never have caused symptoms within a
person’s lifetime). Many of the national policy recommendations
(including for LCHADD) did not assess all of these three
elements. In relation to screening for LCHADD/MTP, the
current review suggests that the evidence on test accuracy is
uncertain. A recent systematic review has examined the potential
benefit of early detection and treatment, comparing the health
outcomes of people with LCHADD/MTP who were treated
with pre-symptomatic dietary management following screen
detection of the conditions compared with people detected
following symptomatic presentation (30). There was some
evidence of an association between timing of intervention and
outcomes, such as mortality, heart problems, liver problems,
visual problems, motor/muscular problems, and hypoglycemia.
However, the majority of included studies found no statistically
significant differences in outcomes between the two groups.
Furthermore, the review identified few studies from which to
draw conclusions and high risks of bias in included studies. There
is no published evidence on overdiagnosis. Overall, the paucity
of data and variability between studies lead to considerable
uncertainty regarding the benefits and harms of screening
for LCHADD/MTP.
Our review has a number of limitations. First, we were not
able to synthesize (meta-analyze) our results numerically due to
a lack of data on FN and TN and because of variability between
screening test methods. Second, we tailored the QUADAS-2
to reflect newborn screening in the UK; this resulted in high
concerns regarding applicability in the patient selection domain,
as screening is often conducted sooner after birth in other
countries. The definition of a high applicability concern is likely
to differ in other countries.
There is currently insufficient evidence to clearly judge test
accuracy. This is driven, in part, by a wide range of markers
and thresholds being used in the included studies: PPV estimates
differed greatly by study, with some suggesting good PPV,
albeit on small numbers of cases. It was not possible for us
to combine data from different studies or determine which
combination of markers and thresholds may yield good accuracy
as results were not presented by marker. Future research could
involve collaboration between researchers to report scores on
a range of relevant markers for cases of LCHAD, cases of
MTP, and in the general population using consistent units.
There is a precedent for this approach in the form of the
Region 4 Stork (R4S) project and accompanying multivariate
pattern recognition software (subsequently developed into
the interactive web tool Collaborative Laboratory Integrated
Reports (CLIR), https://clir.mayo.edu/). The R4S project aimed
“(a) to achieve uniformity of testing panels by MS/MS to
maximize detection of affected newborns within the region;
(b) to improve overall analytical performance; and (c) to
set and sustain the lowest achievable rates of false positive
and false negative results” (31). Reference and disease ranges
for LCHAD/MTP markers were reported for the R4S project
(31). To date, the CLIR tool has been used in a small
number of research projects (32–35). An additional piece
of work should aim to clarify the disease states of babies
who screen negative. This could be achieved in a number
of ways, such as searching hospital/primary care records or
disease registers, or following up samples of babies who have
screened negative.
CONCLUSIONS
Measurement of acylcarnitines in newborn dried blood spots
using TMS may prove to be a useful way to screen for
LCHAD/MTP deficiencies, but currently, there are significant
concerns regarding the high number of false positives in
some of the studies, risks of bias in the studies, heterogeneity
in the methods used, and a lack of data on sensitivity,
specificity, or negative predictive values. Clinicians interested
in the identification of LCHAD/MTP may consider partnership
development across clinical and research networks to address
the knowledge gaps identified from this study, including data
available for long-term follow-up studies and alignment of
diagnostic methodologies.
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